Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Novartis Pharmaceuticals A. G.
EIR
•Novartis Pharmaceuticals A. G.•March 23, 2017

Novartis Pharmaceuticals A. G. – FDA EIR, Mar 23, 2017

Record Details

An FDA inspection of Novartis Pharma A.G.'s Broomfield, CO facility, conducted from March 20-23, 2017, focused on post-marketing adverse drug experience (PADE) reporting under Compliance Program 7353.001. This was the initial PADE inspection for this location, which houses the Pharmacovigilance (PV) Unit for Sandoz US drug products. The inspection resulted in three significant observations listed on an FDA Form 483. The primary issue, a repeat observation from a 2013 inspection, was the failure to report all serious and unexpected adverse drug experiences to the FDA within 15 calendar days. Out of 12,911 serious reports in 2016, 429 were submitted late, with an average delay of 258 days. Secondly, Novartis Pharma A.G. (operating as Sandoz) failed to notify the applicant holder of two serious unclassified adverse events for Nicardipine HCl Injection and did not submit these reports directly to the FDA within 15 days. Lastly, the firm demonstrated a failure to thoroughly review unexplained discrepancies. Investigations into late adverse event submissions lacked adequate root cause analysis, preventive actions, and follow-up. Furthermore, existing procedures did not clearly define roles or processes for tracking and investigating these late submissions. Novartis Pharma A.G. management acknowledged the observations and committed to providing a written response within 15 business days. The FDA also communicated potential legal sanctions, including seizure, injunction, and civil penalties, depending on further agency review.

Company
Novartis Pharmaceuticals A. G.
Inspection date
March 23, 2017
Product type
drugs
Office
Denver District Office
People
  • Jamie Dion (Consumer Safety Officer)
  • Tenzin Jangchup (Performance Improvement Coordinator)
View Company Profile

ID · 860a0720-1b56-47a3-952e-b17a3cf4096f

Violation Codes5
21 CFR 820.10021 CFR 314.80(c)(1)(iii)21 CFR 314.80(c)(1)(i)21 CFR 211.19221 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for Novartis Pharmaceuticals A. G.
  • 483 - 2017-03-23March 23, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novartis Pharmaceuticals A. G.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.